Just days after scornfully assessing [1] a field of weak-kneed pharma companies that were too timid to see the real value in Biogen Idec, the CEO says he may be in the market for a $10 billion acquisition himself. And in an interview with MergerMarkets he said that any takeover target would not have to have late-stage therapies in the pipeline. A bullish-sounding Jim Mullen also told the publication that he expects to see two new therapies launched this year from a pipeline with 15 compounds in Phase II or beyond. Mullen said Biogen Idec will focus on rheumatoid arthritis, lupus and leukemia.
- read the report [2] from the Financial Times
Related Articles:
Biogen CEO: Pharma too wimpy to deal. Report [1]
Biogen shares deflate as it gives up on sale. Report [3]
Is Big Pharma souring on Biogen deal? Report [4]
Sources: Biogen gets bidders, with Pfizer in lead. Report [5]
Links:
[1] http://www.fiercepharma.com/story/biogen-ceo-pharma-too-wimpy-to-deal/2008-01-11?utm_medium=nl&utm_source=link
[2] http://www.ft.com/cms/s/2/2e57daa6-c7d5-11dc-a0b4-0000779fd2ac.html
[3] http://www.fiercebiotech.com/story/biogen-shares-deflate-it-gives-sale/2007-12-13
[4] http://www.fiercepharma.com/story/big-pharma-souring-biogen-deal/2007-11-14
[5] http://www.fiercebiotech.com/story/sources-biogen-gets-bidders-pfizer-lead/2007-11-08